- Time:
The field of cell and gene therapy has seen a wave of exciting advances in the past 12 months. Following the landmark approval of the first CRISPR-based cell therapy in late 2023, investigators have reported further success in clinical trials for liver diseases and various forms of cancer. New gene editing platforms offering longer DNA inserts promise to expand the toolbox of CRISPR-, base and prime editing. But reports of adverse events in several trials, whether caused by the choice of delivery vector or conditioning regimen, emphasize the work that still needs to be done.
Following the success of the inaugural event in 2024, GEN is proud to host The State of Cell and Gene Therapy virtual summit, on January 29, 2025. GEN has gathered a fantastic group of presenters from academia and industry to discuss the latest clinical advances and trends. Through a series of keynote presentations, panel discussions and fireside chats, our speakers will discuss progress and challenges around new technologies, delivery vehicles, and clinical applications.
Highlights of the summit include:
- Opening keynote on the state of CAR-T therapy by 2024 Breakthrough Prize winner Michel Sadelain
- Progress and lessons 12 months after the historic approval of Casgevy, the first CRISPR-based medicine
- Gene therapy for rare and ultra-rare diseases: a fireside chat with Terence Flotte
- The viral vs non-viral delivery debate with Nicole Paulk and Ross Wilson
- Top 5 challenges facing cell and gene therapy with veteran executive Federico Mingozzi
- A roundtable on advances in gene therapy for hearing loss
- Technology breakout sessions hosted by all of the summit sponsors
- And much more!
Registration is entirely free.
Guest Speakers Include
